Key result
Stage 3 and 4 CKD increased the AUC of l-nebivolol (9.94 vs 6.83 ng.h/ml) and d-nebivolol (7.30 vs 4.15 ng.h/ml) compared to controls, while haemodialysis restored values to control levels.
Why the study?
Does chronic kidney disease and haemodialysis alter the pharmacokinetics and pharmacodynamics of a single 10 mg oral dose of nebivolol compared to normal kidney function?
Population
43 adult patients distributed into three groups: healthy volunteers and hypertensive patients with normal…
Comparison
Single oral dose of 10 mg racemic nebivolol vs Healthy volunteers and hypertensive patients…
Design
Cohort
Follow-up
48 hours
Authors
Loading...
May increase nebivolol exposure in stage 3-4 CKD; leaves open need for dose adjustment.
Observational (n=43)
Does chronic kidney disease and haemodialysis alter the pharmacokinetics and pharmacodynamics of a single 10 mg oral dose of nebivolol compared to normal kidney function?
Absolute Event Rate: 9.94% vs 6.83%
Stage 3 and 4 CKD increases plasma concentrations of nebivolol enantiomers, whereas haemodialysis restores pharmacokinetic parameters to values similar to those with normal kidney function.
Neves et al. (2016) conducted an observational in Chronic kidney disease (n=43). Stage 3 and 4 chronic kidney disease vs. Normal kidney function was evaluated on Area under the concentration-time curve (AUC) of l-nebivolol (ng.h/ml). Stage 3 and 4 CKD increased the AUC of l-nebivolol (9.94 vs 6.83 ng.h/ml) and d-nebivolol (7.30 vs 4.15 ng.h/ml) compared to controls, while haemodialysis restored values to control levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: